First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis

• Main Authors: Alessandro Ottaiano (Author), Alfonso De Stefano (Author), Monica Capozzi (Author), Anna Nappi (Author), Chiara De Divitiis (Author), Carmela Romano (Author), Lucrezia Silvestro (Author), Antonino Cassata (Author), Rossana Casaretti (Author), Salvatore Tafuto (Author), Michele Caraglia (Author), Massimiliano Berretta (Author), Guglielmo Nasti (Author), Antonio Avallone (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab.Patients and Methods: Randomized, phase II or III, clinical trials reporting...